Inovio Pharmaceuticals Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer.
This open-label study, called HPV-004, will evaluate INO-3112 in 20 female subjects, with inoperable invasive cervical cancer.
This cervical cancer study is being conducted at the University of Chicago Medical Centre.
Colonial Coal International Corp. (TSX.V:CAD) is pleased to announce that the British Columbia Ministry of Energy and Mines has issued a total of 26 new coal licenses the Company’s Flatbed and Huguenot properties.
The 19 coal licenses issued for the Huguenot property principally cover potential down-dip extensions to previously defined and reported resources plus additional resource potential east of the currently defined deposit; most of these new licences are located along trend from other coal projects located to the northwest
The Flatbed property is now comprised of seven coal licenses that cover a total of 9,077 hectares.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report new data supporting the positive sexual functional preservation profile of NX-1207, the Company’s lead compound in Phase 3 development for the treatment of prostate enlargement (BPH or benign prostatic hyperplasia) and Phase 2 development for localized prostate cancer.
Inovio Pharmaceuticals, Inc. (NYSE: INO) has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide rights to technology and intellectual property for novel synthetic therapies against cancer, infectious diseases and new immune activators.